Stocktoria
Denali Therapeutics Inc. DNLI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2017-12-08
Denali Therapeutics Inc. statistics & valuation
Market cap$4.1B
P / B4.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -59.5% | -314.2% | -607.8% |
| Net margin | — | — | -43.9% | -300.6% | -597.2% |
| FCF margin | — | — | -112.2% | -242.1% | -451.9% |
| Return on assets | -44.8% | -30.8% | -12.6% | -22.3% | -20.7% |
| Return on equity | -50.6% | -34.4% | -14.1% | -31.3% | -30.2% |
| Current ratio | 9.16 | 8.46 | 13.65 | 3.77 | 2.37 |
| Revenue growth | — | -100.0% | 204.7% | 122.9% | -85.5% |
Source: SEC EDGAR filings · CIK 0001714899 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.